How do you decide whether to obtain dental evaluation to reduce the risk of medication-related osteonecrosis of the jaw prior to initiating non-urgent bone-modifying agent therapy?   

I have a practice that I send all patients, even edentulous patients, for a dental screening examination if they have a non-emergent need bone-modifying agents (BMAs). That recommendation comes from osteonecrosis guidelines published in J Clin Oncol 2019. The reason for this recommendation is when s...